RFK, Jr. Warned FDA Three Months Ago About Ingredient in Pfizer COVID Vaccine That Likely Caused Life-Threatening Reaction in Two UK Healthcare Workers

RFK, Jr. Warned FDA Three Months Ago About Ingredient in Pfizer COVID Vaccine That Likely Caused Life-Threatening Reaction in Two UK Healthcare Workers

An investigation this week identified polyethylene glycol (PEG) as the likely reason two people in the UK suffered anaphylaxis after receiving Pfizer's COVID vaccine. In September, CHD Chairman RFK, Jr. warned the FDA that PEG in COVID vaccines could lead to severe allergic

by <u>Lyn Redwood, RN, MSN</u>, <u>The Defender</u>, Children's Health Defense December 11, 2020

On Dec. 2, Britain's Medicines and Healthcare Products Regulatory Agency (MHRA) became the first in the world to approve a COVID-19 vaccine developed by Germany's BioNTech and Pfizer.

A mass vaccination campaign that targeted frontline workers to receive the vaccine began on Dec. 8. Within 24 hours of launching the campaign, <u>MHRA acknowledged</u> two reports of anaphylaxis and one report of a possible allergic reaction.

<u>Reuters</u> reported late yesterday afternoon that an investigation into the <u>anaphylactic reactions</u> by MHRA has identified <u>polyethylene glycol</u>, or PEG, as the likely culprit.

Imperial College London's Paul Turner, an expert in allergy and immunology who has been advising the MHRA on its revised guidance, told Reuters: "The ingredients like PEG which we think might be responsible for the reactions are not related to things which can cause food allergy. Likewise, people with a known allergy to just one medicine should not be at risk."

It was also reported that PEG, which helps to stabilize the shot, is not in other types of vaccines.

The statements by Turner that "PEG is not in other types of vaccines" and that people with allergies to "just one medicine should not be at risk" are a failed attempt to provide false assurances and are patently untrue.

Moderna, Pfizer/BioNTech and Arcturus Therapeutics COVID vaccines all utilize a never-before-approved messenger RNA (mRNA) technology, an experimental approach designed to turn the body's cells into viral protein-making <u>factories</u>. This technology involves the use of lipid nanoparticles (LNPs) that <u>encapsulate</u> the mRNA to protect them from degradation and promote cellular uptake.

The LNP formulations in the three COVID-19 mRNA vaccines are "PEGylated," meaning that the vaccine nanoparticles are coated with a synthetic, non-degradable and <u>increasingly</u> controversial PEG.

<u>COVID mRNA vaccines</u> are not the only vehicle for PEG involvement in COVID-19 vaccine production. Researchers at Germany's Max Planck Institute report developing a process for COVID-19 vaccine production to purify virus particles at "high yield." The process involves <u>adding PEG</u> to a virus-containing liquid and passing the liquid through membranes.

On Sept. 25, Robert F. Kennedy, Jr., chairman and chief legal counsel for Children's Health Defense (CHD), notified the Steven Hahn, director of the U.S. Food and Drug Administration (FDA), Dr. Peter Marks director of FDA's Center for Biologics Evaluation and Research and Anthony Fauci, director of the National Institute for Allergy and Infectious Diseases, of the serious and possibly life-threatening anaphylactic potential of PEG.

From: Robert F. Kennedy Jr. robert.kennedyjr@childrenshealthdefense.org

Sent: Friday, September 25, 2020 6:02 PM

To: FDA Commissioner septem.Hahn@fda.hhs.gov; Marks, Peter peter.Marks@fda.hhs.gov>

Cc: Congressman Posey rockledger@aol.com; Buchanan, Lisa K (OS) lisa.Buchanan@hhs.gov; senator@kaine.senate.gov; Doepel, Laurie K (NIH) laurie.doepel@nih.gov; Fauci, Anthony S (NIH) afauci@niaid.nih.gov; hugh.auchincloss@nih.gov; john.mascola@nih.gov; cliff.lane@nih.gov

Drs. Hahn and Marks,

I'm writing to you today regarding Moderna's mRNA vaccine in development that contains polyethylene glycol (PEG). The use of PEG in drugs and vaccines is increasingly controversial due to the well-documented incidence of adverse PEG-related immune reactions, including life-threatening anaphylaxis. Roughly seven in ten Americans may already be sensitized to PEG, which may result in reduced efficacy of the vaccine and an increase in adverse side effects. It is critical that FDA's regulatory scrutiny of Moderna be beyond reproach, since other manufacturers will look to Moderna as a role model for their own safety studies. FDA's review of Moderna's vaccine should be a template for rigorous protocols that unambiguously elevate safety above political or monetary considerations. I urge that you give priority to your agency's duty to protect public health and the rights of trial participants to genuine informed consent regarding the use of PEG in. We ask you to order Moderna to immediately inform all trial participants of the risk for allergic reactions from PEG, and to carefully monitor and publicly disclose allergic reactions potentially associated with PEG.

Please see the attached for more information.

Subject: Letter from RFK, Jr. on concerns with Moderna's COVID vaccine

Sincerely,	

Robert F. Kennedy, Jr.

CHD received the following <u>response</u> from the FDA, on Dec. 2, but has not yet received a response from Fauci.

RE: Letter from RFK, Jr. on concerns with Moderna's COVID vaccine

To: robert.kennedyjr@childrenshealthdefense.org

Dear Mr. Kennedy,

This is in response to your letter to Commissioner Hahn and Dr. Peter Marks regarding Moderna's investigational mRNA vaccine for the prevention of COVID-19. I apologize for the delay in responding.

Thank you for sharing your comments regarding Moderna's vaccine and FDA's review process for this and other COVID-19 vaccines.

FDA is a science-based regulatory agency and is focused on ensuring that vaccines that are approved or authorized for use are supported by the best available scientific and clinical evidence and that the statutory requirements for safety and effectiveness are met. In this regard, FDA is using all appropriate regulatory authorities and providing scientific and regulatory advice to facilitate the development and availability of safe and effective therapeutics and vaccines to address COVID-19.

We recommend that you reach out to Moderna directly to inquire about the informed consent for the firm's investigational COVID-19 vaccine.

Thank you again for contacting FDA.

Best regards,

Lorrie H. McNeill

Director

Office of Communication, Outreach and Development Center for Biologics Evaluation and Research U.S. Food and Drug Administration



In earlier communications with Moderna scientists regarding the controversial use of PEG in the company's COVID-19 vaccine due to the potential for life-threatening anaphylaxis and need for pre-screening for PEG antibodies prior to vaccine administration, they insisted that the existence of PEG antibodies was purely hypothetical and underserving of concern:

"Pre-screening populations based on hypothesized biomarkers, such as anti-PEG antibodies, is not a strategy currently employed in our clinical trials."

Given the recent evidence of PEG anaphylaxis in Pfizer mRNA vaccine recipients, I wonder if FDA and vaccine manufacturers will now reconsider their position.

An extensive <u>review of PEG</u> therapeutics, published in 2013, documented adverse effects of PEGylation and questioned the wisdom behind the continued use of PEG in drug development. The authors concluded that "the accumulating evidence

documenting the detrimental effects of PEG on drug delivery make it imperative that scientists in this field break their dependence on PEGylation."

The statement by Turner that "people with a known allergy to just one medicine should not be at risk," is also not true.

A <u>2018 study</u>, "Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized" reports there are more than 1,000 products, including prescription drugs, that contain PEG. (See chart below for detailed descriptions of PEG containing drugs.)

The decision to allow people with other medication allergies to receive vaccines that utilize PEG in the manufacturing or delivery of the vaccine is a very risky proposition — especially given that Pfizer has said people with a history of severe adverse allergic reactions to vaccines or the candidate's ingredients were excluded from their late stage trials.

We have no idea what the incidence of allergy or anaphylactic reactions will be once Pfizer begins global distribution of the vaccine, without such exclusions.

A <u>2016 study</u> reported detectable and sometimes high levels of anti-PEG antibodies in approximately <u>72% of contemporary human samples</u> and about 56% of historical specimens from the 1970s through the 1990s. The population's <u>increased exposure</u> to PEG-containing products since the 1990's makes it natural to assume that anti-PEG antibodies will continue to be widespread.

As approval of PEGylated mRNA vaccines for COVID-19 occurs, the uptick in exposure to injected PEG products will be unprecedented and potentially disastrous.

While four out of five doctors regularly prescribe PEGylated drugs, only one out of five are aware of the potential for

anti-PEG antibody responses. And only a third even know that PEG is in the drugs that they are prescribing.

A Vanderbilt University researcher agrees that there is a widespread <u>lack of recognition</u> that PEG hypersensitivity is possible, much less that it manifests on a regular basis. While it has been recommended to screen patients for anti-PEG antibody levels "prior to administration of therapeutics containing PEG" such testing is currently only available in research settings.

In a declaration effective Feb. 4, the Secretary of Health and Human Services invoked the <u>Public Readiness and Emergency Preparedness Act</u> (<u>PREP Act</u>) and declared Coronavirus Disease 2019 (COVID-19) to be a public health emergency warranting liability protections for covered countermeasures, including vaccines.

The fact that the FDA has abdicated its responsibility for assuring the safety of COVID vaccines to vaccine manufacturers means we are on our own to study the science, and weigh the benefits and risks of all drugs and vaccines.

CHD will continue to monitor this important safety issue in an effort to keep you well informed on the science and public policies surrounding COVID-19 vaccine development.

Descriptions of PEG containing drugs:

Effective Amount	Route of	Product Group	Product Examples		
(Strength)	Entry	Drug Indication Category Condition Treated	Product Examples		
Grams	Oral	Powder for Solution Bowel evacuant/laxative	Clearlax, CoLyte, EZZGO, Gavilax, GaviLyte, Glycolax, Golytely, Healthylax, Moviprep, Nulytely,		
Milligrams	Parenteral	Intramuscular	Polyethylene Glycol 3350, TriLyte		
		Contraceptive Steroid	Depo-Provera Depo-Medrol, Methylprednisolone acetate		
		Intra-articular Steroid	Depo-Medrol, Methylprednisolone acetate		
dicrograms/Unknown	Oral	Film Coated Tablet Cardiovascular	seeps mean of menigipa emissioned decided		
		Angina Essential Hypertension	Ranexa Amlodipine-Atorvastatin, Amlodipine-Olmesartan, Amlodipine-Valsartan, Amlodipine-Valsartan		
		District Hypertension	Hydrochlorothiazide, Avalide, Azor, Byvalson, Irbesartan-Hydrochlorothiazide, Labetalol, Losartan, Losartan-Hydrochlorothiazide, Moexipril-Hydrochlorothiazide, Valsartan, Valsartan-		
		Pulmonary Hypertension	Hydrochlorothiazide Letairis, Sildenafil		
		Endocrine Diabetes			
		Fibrate Statin	Glipizide-Metformin, Invokamet, Invokana, Janumet XR, Metformin, Pioglitazone-Metformin, Steglatro		
		Gastroenterology Gallstone Dissolution	Gemfibrozil Amlodipine-Atorvastatin, Fluvastatin, Rosuvastatin, Simvastatin		
		Primary Biliary Cirrhosis Agent	Ursodiol		
		Infectious Diseases Antibiotic	Ocaliva		
		Antifungal Hepatitis C	Amoxicillin, Doxycycline, Minocycline, Solodyn		
		HIV Malaria	Griseofulvin, Noxafil, Voriconazole Epclusa, Harvoni, Mavyret, Moderiba, Ribasphere Ribapak, Ribavirin, Technivie, Viekira		
		Neurology	Atripla, Descovy, Entecavir, Isentress, Kaletra, Norvir, Prezista, Stribild, Tybost, Zidovudine Chloroquine, Hydroxychloroquine		
		Dementia Migraine			
		Pain Seizure	Donepezil Sumatriptan		
		Oncology	Aleve, Morphine ER, Tramadol, Xartemis XR Briviact, Gralise, Keppra, Keppra XR, Levetiracetam		
		Antineoplastic Aromatase Inhibitor			
		Psychiatry	Bosulif, Cotellic, Tagrisso, Zelboraf Letrozole		
		Antipsychotic Depression			
		Insomnia	Nuplazid Bupropion, Desvenlafaxine, Fluoxetine, Protriptyline		
		Rheumatology Rheumatoid Arthritis	Eszopiclone		
			Xeljanz		
		Urology Erectile Dysfunction			
		Overactive bladder	Sildenafil		
		Other Anticoagulation	Trospium		
		Antihistamine Chelating Agent	Xarelto		
		Cystic Fibrosis Phosphate Binder	Cetirizine, Hydroxyzine Ferriprox		
		Tablet	Kalydeco, Orkambi Sevelamer		
		Cardiovascular Angina			
		Antiplatelet Essential Hypertension	Metoprolol tartrate, nitroglycerin		
		Pulmonary Hypertension	Clopidogrel Nifedipine, Spironolactone, Teveten, Valsartan		
		Endocrine Diabetes	Orenitram		
		Fibrate	Glipizide-Metformin, Rosiglitazone		
		Neurology Pain	Fenofibrate, Gemfibrozil		
		Seizure	Aleve, Esbriet, Exalgo, Hysingla ER, Ibuprofen, Morphine		
		Psychiatry Antipsychotic	Divalproex, Keppra		
		Depression Stimulant	Risperidone		
		Other	Phenelzine, Tranylcypromine, Venlafaxine, Wellbutrin SR Benzphetamine, Methylphenidate		
		Antibiotic Antihistamine			
		Antineoplastic Contraceptive	Amoxicillin, Metronidazole Famotidine		
		Decongestant	Lysodren, Stivarga, Zytiga Dasetta, Elinest, Falessa, Falmina, Juleber, Larin, Larin FE, Levonest, Loryna, Mono-Linyah,		
		Gallstone dissolution Leukotriene Antagonist Overactive bladder	Northinodrone, Philith, Setlakin, Sharobel, Sveda, Tri-Linyah, Wera Zephrex-D Ursodiol		
		Overactive bladder Capsule	Ursodioi Montelukast Oxybutynin ER		
		Antiplatelet Stool softener			
		Proton Pump Inhibitor	Aspirin-Dipyridamole DOK		
		Suspension Antitussive	Omeprazole		
		Anticussive.	Delsym, Delsym ER, Tussionex		
	Parenteral	Intravenous			
		Hemophilia Antitrypsin Deficiency	Recombinate, Hemofil M Aralast NP		
		Subcutaneous			
		Cryopyrin-associated period syndromes	Arcalyst		
	Topical	Ointment Acne	Bensal HP		
		Antibacterial Anesthetic	Mupirocin Lidocaine		
		Cream	Book Conference on the Confere		
		Acne Antifungal	Proactiv Clarifying Night Acne Treatment Ting, Tolnaftate Elucationide		
		Steroid	Fluocinonide		
		Gel Anesthetic	Americaine, Astero, Astra-Dent, Benzocaine, Candee Caine, Comfortcaine, Topex		
		Lotion Acne	Proactive Gentle Formula Clearifying Night		
		30/305/11	Froattive Gentie Formula Clearnying Night		
		Solution Antibacterial	Pre-Scrub II Surgical Hand Scrub		
		Powder for Reconstitution Hemostatic agent	Recothrom		
	I				
	Nasal	Solution	Reconium		